Healio

FDA approves Zymfentra as first subcutaneous infliximab for ulcerative colitis, Crohn’s

Please provide your email address to receive an email when new articles are posted on . The FDA approved the subcutaneous formulation of Celltrion USA’s Zymfentra as maintenance therapy for patients ...
Monthly Prescribing Reference

Zymfentra, a Subcutaneous Formulation of Infliximab, Approved for IBD

Credit: Celltrion USA. Zymfentra is a subcutaneous formulation of Inflectra, a biosimilar to Remicade. Zymfentra is indicated as maintenance treatment only; all patients must complete an IV induction ...
Hosted on MSN

New ECCO data show subcutaneous (SC) infliximab (Remsima SC) effectively recaptures and maintains disease control after drug holiday

Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response ...
Healio

Subcutaneous infliximab could ‘transform’ how patients with IBD navigate care

Please provide your email address to receive an email when new articles are posted on . Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo ...
Medscape

International Approvals: Lyrica and Remicade

October 16, 2006 — The European Commission has approved pregabalin capsules for the treatment of central neuropathic pain associated with spinal cord injury, stroke, and multiple sclerosis; and ...
PharmiWeb

Celltrion presents positive real-world data on switching from intravenous (IV) to subcutaneous (SC) infliximab at UEG Week 2025 Meet the Expert sessions

INCHEON, SOUTH KOREA, OCTOBER 6 2025 – Celltrion, Inc. today showcased real-world evidence supporting the use of subcutaneous (SC) infliximab, confirming the efficacy and safety of switching to SC ...
Business Wire

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...
Medscape

Meta-Analysis Favors SubQ Infliximab Biosimilar Over Vedolizumab in Crohn's Disease

An infliximab biosimilar (infliximab-axxq) delivered via subcutaneous injection was superior to intravenous vedolizumab (Entyvio) for induction and maintenance therapy of Crohn's disease (CD), ...
Business Wire

High Infliximab Trough Levels Are Associated With Low Risk of Relapse When Switching to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease, Suggests New Data ...

INCHEON, South Korea--(BUSINESS WIRE)--Today, Celltrion Healthcare announced two new data sets on the SC formulation of infliximab, Remsima ® (CT-P13) in IBD, at the European Crohn’s and Colitis ...
Healthline

Remicade and Cost: What You Need to Know

Remicade comes as a powder. A healthcare professional mixes the powder with liquid to form a solution, which they give as an intravenous (IV) infusion. (This is an injection into a vein given over ...
ksn.com

ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.

JERSEY CITY, N.J., March 17, 2024 /PRNewswire/ -- Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab. [1] ZYMFENTRA is the ...